ALB and neoplasm: The in vivo characterization of the novel radioligands hereinalong with the data from our previous study highlight that the increasein tumor uptake does only marginally originate from off-target bindingvia the albumin-binding moiety itself or retention of the albumin-boundradioligand in the tumor tissue independent of SST2-binding.Instead, we propose that the albumin-bound radioligand is able tobind to SST2, albeit with a lower affinity compared tothe free radioligand, which is deduced from saturation binding analysesin the presence of albumin.